Electrolytic deposition of calcium etidronate drug coating on titanium substrate

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 72, Issue 1, 2005, Pages 43-51

  Duan, Ke ^a   Fan, Yuwei ^a   Wang, Rizhi ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Coating(s); Drug delivery release; Electrolytic deposition; Osteolysis; Titanium (alloys)

Indexed keywords

CALCIUM COMPOUNDS; CERAMIC COATINGS; COATING TECHNIQUES; CONCENTRATION (PROCESS); DRUG THERAPY; FOURIER TRANSFORM INFRARED SPECTROSCOPY; HIP PROSTHESES; IONIZATION; MASS SPECTROMETRY; SALTS; SCANNING ELECTRON MICROSCOPY; SUBSTRATES; TITANIUM; X RAY DIFFRACTION;

CALCIUM ETIDRONATE; DRUG COATINGS; ELECTROSPRAY-IONIZATION-MASS SPECTROMETRY (ESI-MS);

ELECTRODEPOSITION;

ETIDRONIC ACID; TITANIUM;

ARTICLE; CHEMICAL STRUCTURE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; ELECTROLYSIS; ELECTROSPRAY MASS SPECTROMETRY; IMPLANT; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; OSTEOCLAST; SCANNING ELECTRON MICROSCOPE; X RAY DIFFRACTION;

ALLOYS; ARTHROPLASTY, REPLACEMENT, HIP; CALCIUM; CRYSTALLIZATION; DRUG DELIVERY SYSTEMS; ELECTROLYTES; ETIDRONIC ACID; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR STRUCTURE; PRECIPITATION; SOLUTIONS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPECTRUM ANALYSIS; TITANIUM;

EID: 11144312627     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbm.b.30112     Document Type: Article

References (31)

1. National Institute of Health. Total hip replacement consensus statement 1994, vol. 12. Bethesda, MD: NIH; 1994. p 1-31.
2. Wright TM, Goodman SB, editors. Implant wear in total joint replacement: Clinical and biologic issues, material and design considerations. Am Acad Orthopaed Surg 2001;3-7.
3. Harris WH. The problem is osteolysis. Clin Orthop 1995;311: 46-53.
4. Muratoglu OK, Kurtz SM. Alternate bearing surfaces in hip replacement. In: Sinha RK, editor. Hip replacements: Current trends and controversies. New York: Marcel Dekker; 2002. p 1-46.
5. Fleisch H. Bisphosphonates in bone disease: From the laboratory to the patient, 4th ed. San Diego, CA: Academic Press; 2000.
6. Sabokbar A, Fujikawa Y, Murray DW, Athanasou NA. Bisphosphonates in bone cement inihibt PMMA particle induced bone resorption. Ann Rheum Dis 1998;57:614-618.
7. Schwarz EM, Ben EB, Lu AP, Goater JJ, Mollano AV, Rosier RN, Puzas JE, Okeefe RJ. Quantitive small-animal surrogate to evaluate drug efficacy in prevention wear debris-induced osteolysis. J Orthop Res 2000;18:849-855.
8. Horowitz SM, Algan SA, Purdon MA. Pharmacologic inhibition of particulate-induced bone resportion. J Biomed Mater Res 1996;31:91-96.
9. Shanbhag RS, Hasselman CT, Rubash CE. Inhibition of wear debris mediated osteolysis in a canine total hip arthoplasty model. Clin Orthop 1997;344:33-43.
10. Little DG, Smith NC, Williams, P, Bridody JN, Bilston LE, Smith EJ, Gardiner EM, Cowell C. Zoledronate acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res 2003;18:1300-1307.
11. Meraw SJ, Reeve CM. Qualitative analysis of peripheral peri-implant bone and influence of alendronate sodium on early bone regeneration. J Peridontol 1999;70:1228-1233.
12. Yoshinari M, Oda Y, Inoure T, Matsuzaka K, Shimono M. Bone response to calcium phosphate-coated and bisphosphonate-immobilized titanium implants. Biomaterials 2002;23:2879-2885.
13. Ganguli A, Henderson C, Grant MH. The interaction of bisphosphonates in solution and as coatings on hydroxyapatite with ostoeblasts. J Mater Sci Mater Med 2002;13:923-931.
14. Denissen H, Martinetti R, van Lingen A, van den Hoof A. Normal osteoconduction and repair in and around submerged highly bisphosphonate- complexed hydroxyapatite implants in rat tibiae. J Peridontal 2000;71:272-278.
15. Browning FH, Fogler FS. Effect of precipitating conditions on the formation of calcium-HEDP precipitates. Langmuir 1995; 12:5231-5238.
16. Redepenning J, Mcisaac JP. Electrocyrystallation of brushite coatings on prosthetic alloys. Chem Mater 1990;2:625-627.
17. Shirkhanzadeh M. Bioactive calcium-phosphate coatings prepared by elecrodeposition. J Mater Sci Lett 1991;10:1415-1417.
18. Zhitomirshy I. Cathodic electrodeposition of ceramic and organoceramic materials. Fundamental aspects. Adv Colloid Interface Sci 2002;97:279-317.
19. Liggett SJ. Determination of ethane-1-hydroxy-1,1-diphosphonic acid (EHDP) in human feces and urine. Biochem Med 1973;7:68-77.
20. Johnston TP, Schoen FJ, Levy RJ. Prevention of calcification of bioprosthetic heart valve leaflets by Ca2+ diphosphonate pretreatment. J Pharmaceut Sci 1988;77:740-744.
21. Thomas LC. Interpretation of the infrered spectra of organophosphorous compounds. London: Heydon; 1974.
22. Zhang JM, Lin CJ, Feng ZD, Tian ZW. Mechanistic studies of electrodeposition for bioceramic coatings of calcium phosphates by an in situ pH-microsensor techniques. J Electron Chem 1998; 452:235-240.
23. Kuo MC, Yen SK. The process of electrochemical deposited hydroxyaptite coatings on biomedical titanium at room temperature. Mater Sci Eng C 2002;20:153-150.
24. Qing XZ, Tsai EW, Sakuma T. Pharmaceutical application of gas chromatography-mass spectrometry. 2. Ion chromatography ion-spray mass-spectrometric characterization of alendronate. J Chromatogr A 1994;686:204-212.
25. Huikko K, Kostiainen R. Analysis of bisphosphonates by capillary electrophoresis-electrospray ionization mass spectrometry. J Chromatogr A 2000;872:289-298.
26. Zaki MT, Ismail MI, Rizkalla EN. Metal chelates of phosphonate-containing ligands: VII. Analytical applications of 1-hydroxyethane-1,1-diphosphonic acid. Microchem J 1984;30:6-11.
27. Ostovic D, Brenner G. Development of subcutaneous and intramuscular formulations of calcium alendronate salts. Drug Dev Ind Pharm 1995;21:1157-1169.
28. Osterman T, Virtamo T, Lauren L, Kippo K, Pasanen I, Hunnuniemi R, Vaananen K, Sellman R. Slow-release clodronate in prevention of inflammation and bone loss associated with adjuvant arthritis. J Pharmacol Exp Ther 1997;280:1001-1007.
29. Garcia-Moreno C, Serrano S, Nacher M, Farre M, Diez A, Marinoso ML, Carbonell J. Mellivobsky L, Nogues X, Ballester J, Aubia J. Effect of alendronate on cultured normal human osteoblasts. Bone 1998;22:233-239.
30. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramanian M, Ingle JN, Spelsberg TC. Bisphosphonates directly regulate cell proliferation, differentiation and gene expression in human osteoblasts. Cancer Res 2000;60:6001-6007.
31. Im Gun-II, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and manuration by bisphosphonates. Biomaterials 2004;25:4105-4115.